警惕瑞舒伐他汀在中国的不实宣传
2010年，美国FDA批准瑞舒伐他汀为心血管事件初级预防用药。中国大陆也开始广泛使用。但与美国大量专家质疑瑞舒伐他汀不同， 不少中国厂家和专家吹嘘瑞舒伐他汀是最好的他汀。JUPITER trial研究表明瑞舒伐他汀比安慰剂增加了27%患者患糖尿病，AURORA trial研究表明瑞舒伐他汀没有降低患者全因死亡率。同时瑞舒伐他汀肾毒性也较高。FDA建议亚洲人服用瑞舒伐他汀副作用较高，建议减量使用。
有些药商吹嘘10mg瑞舒伐他汀等同于20mg阿托伐他汀。其实STELLAR Trial显示在血脂偏低的低危患者10mg瑞舒伐他汀等同于20mg阿托伐他汀，危险因素较高的患者10mg瑞舒伐他汀等同于10mg阿托伐他汀.
本人就有深刻教训。本人母亲2008 LM-LAD植入2枚支架。回顾她术后至今10次血脂检查，坚持服用20mg阿托伐他汀LDL一直控制在100mg/dl以下，有时低于70 mg/dl。2011年9月参加药商搞得宣教活动后接受10mg瑞舒伐他汀，LDL一直在100mg/dl以上。本月心绞痛发作2次， CTA示LCX病变进展。所以奉劝大家不要被药商的宣传迷惑。
参见维基百科：
http://en.wikipedia.org/wiki/Rosuvastatin#cite_note-FDAlabel-1
欺负咱们不会看英文信息吗？
The products include: Lipitor (atorvastatin), Lescol (fluvastatin), Mevacor (lovastatin), Altoprev (lovastatin extended-release), Livalo (pitavastatin), Pravachol (pravastatin), Crestor (rosuvastatin), and Zocor (simvastatin). Combination products include: Advicor (lovastatin/niacin extended-release), Simcor (simvastatin/niacin extended-release), and Vytorin (simvastatin/ezetimibe).
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm293623.htm
FDA Advisory Targets Asian Patients
THE NATION
Doctors are warned that a full dose of cholesterol drug Crestor could raise the risk of side effects.
March 03, 2005|Ricardo Alonso-Zaldivar | Times Staff Writer
WASHINGTON — The Food and Drug Administration urged doctors Wednesday to use caution in prescribing the cholesterol drug Crestor to patients of Asian heritage, but said that overall the medication carried no higher risk of serious side effects than its competitors.
Issuing a public health advisory and changes to prescribing information for doctors, the agency said that Asian patients should be started at the lowest approved dose, 5 milligrams a day.
http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm293330.htm
Reports of Memory Loss
FDA has been investigating reports of cognitive impairment from statin use for several years. The agency has reviewed databases that record reports of bad reactions to drugs and statin clinical trials that included assessments of cognitive function.
The reports about memory loss, forgetfulness and confusion span all statin products and all age groups. Egan says these experiences are rare but that those affected often report feeling “fuzzy” or unfocused in their thinking.
In general, the symptoms were not serious and were reversible within a few weeks after the patient stopped using the statin. Some people affected in this way had been taking the medicine for a day; others had been taking it for years.
What should patients do if they fear that statin use could be clouding their thinking? “Talk to your health care professional,” Egan says. “Don’t stop taking the medication; the consequences to your heart could be far greater.”
back to top
The Risk of Diabetes
Diabetes occurs because of defects in the body’s ability to produce or use insulin—a hormone needed to convert food into energy. If the pancreas doesn't make enough insulin or if cells do not respond appropriately to insulin, blood sugar levels in the blood get too high, which can lead to serious health problems.
A small increased risk of raised blood sugar levels and the development of Type 2 diabetes have been reported with the use of statins.
“Clearly we think that the heart benefit of statins outweighs this small increased risk,” says Egan. But what this means for patients taking statins and the health care professionals prescribing them is that blood-sugar levels may need to be assessed after instituting statin therapy,” she says.
March 4, 2012
The Diabetes Dilemma for Statin Users
By ERIC J. TOPOL
San Diego, Calif.
We’re overdosing on cholesterol-lowering statins, and the consequence could be a sharp increase
in the incidence of Type 2 diabetes.
If there were a major suppression of heart attacks or strokes or deaths, that might be justified.
But in patients who have never had heart disease and are taking statins to lower their risk (socalled
primary prevention), the reduction of heart attacks and other major events is only 2 per
100. And we don’t know who the 2 per 100 patients are who benefit or the one per 200 who will
get diabetes! Moreover, the margin of benefit to risk is quite narrow. 2 1 2 下一页 尾页
2010年，美国FDA批准瑞舒伐他汀为心血管事件初级预防用药。中国大陆也开始广泛使用。但与美国大量专家质疑瑞舒伐他汀不同， 不少中国厂家和专家吹嘘瑞舒伐他汀是最好的他汀。JUPITER trial研究表明瑞舒伐他汀比安慰剂增加了27%患者患糖尿病，AURORA trial研究表明瑞舒伐他汀没有降低患者全因死亡率。同时瑞舒伐他汀肾毒性也较高。FDA建议亚洲人服用瑞舒伐他汀副作用较高，建议减量使用。
有些药商吹嘘10mg瑞舒伐他汀等同于20mg阿托伐他汀。其实STELLAR Trial显示在血脂偏低的低危患者10mg瑞舒伐他汀等同于20mg阿托伐他汀，危险因素较高的患者10mg瑞舒伐他汀等同于10mg阿托伐他汀.
本人就有深刻教训。本人母亲2008 LM-LAD植入2枚支架。回顾她术后至今10次血脂检查，坚持服用20mg阿托伐他汀LDL一直控制在100mg/dl以下，有时低于70 mg/dl。2011年9月参加药商搞得宣教活动后接受10mg瑞舒伐他汀，LDL一直在100mg/dl以上。本月心绞痛发作2次， CTA示LCX病变进展。所以奉劝大家不要被药商的宣传迷惑。
参见维基百科：
http://en.wikipedia.org/wiki/Rosuvastatin#cite_note-FDAlabel-1
欺负咱们不会看英文信息吗？
The products include: Lipitor (atorvastatin), Lescol (fluvastatin), Mevacor (lovastatin), Altoprev (lovastatin extended-release), Livalo (pitavastatin), Pravachol (pravastatin), Crestor (rosuvastatin), and Zocor (simvastatin). Combination products include: Advicor (lovastatin/niacin extended-release), Simcor (simvastatin/niacin extended-release), and Vytorin (simvastatin/ezetimibe).
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm293623.htm
FDA Advisory Targets Asian Patients
THE NATION
Doctors are warned that a full dose of cholesterol drug Crestor could raise the risk of side effects.
March 03, 2005|Ricardo Alonso-Zaldivar | Times Staff Writer
WASHINGTON — The Food and Drug Administration urged doctors Wednesday to use caution in prescribing the cholesterol drug Crestor to patients of Asian heritage, but said that overall the medication carried no higher risk of serious side effects than its competitors.
Issuing a public health advisory and changes to prescribing information for doctors, the agency said that Asian patients should be started at the lowest approved dose, 5 milligrams a day.
http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm293330.htm
Reports of Memory Loss
FDA has been investigating reports of cognitive impairment from statin use for several years. The agency has reviewed databases that record reports of bad reactions to drugs and statin clinical trials that included assessments of cognitive function.
The reports about memory loss, forgetfulness and confusion span all statin products and all age groups. Egan says these experiences are rare but that those affected often report feeling “fuzzy” or unfocused in their thinking.
In general, the symptoms were not serious and were reversible within a few weeks after the patient stopped using the statin. Some people affected in this way had been taking the medicine for a day; others had been taking it for years.
What should patients do if they fear that statin use could be clouding their thinking? “Talk to your health care professional,” Egan says. “Don’t stop taking the medication; the consequences to your heart could be far greater.”
back to top
The Risk of Diabetes
Diabetes occurs because of defects in the body’s ability to produce or use insulin—a hormone needed to convert food into energy. If the pancreas doesn't make enough insulin or if cells do not respond appropriately to insulin, blood sugar levels in the blood get too high, which can lead to serious health problems.
A small increased risk of raised blood sugar levels and the development of Type 2 diabetes have been reported with the use of statins.
“Clearly we think that the heart benefit of statins outweighs this small increased risk,” says Egan. But what this means for patients taking statins and the health care professionals prescribing them is that blood-sugar levels may need to be assessed after instituting statin therapy,” she says.
March 4, 2012
The Diabetes Dilemma for Statin Users
By ERIC J. TOPOL
San Diego, Calif.
We’re overdosing on cholesterol-lowering statins, and the consequence could be a sharp increase
in the incidence of Type 2 diabetes.
If there were a major suppression of heart attacks or strokes or deaths, that might be justified.
But in patients who have never had heart disease and are taking statins to lower their risk (socalled
primary prevention), the reduction of heart attacks and other major events is only 2 per
100. And we don’t know who the 2 per 100 patients are who benefit or the one per 200 who will
get diabetes! Moreover, the margin of benefit to risk is quite narrow. 2 1 2 下一页 尾页